Rat and human liver cytochrome P-450 isoform metabolism of ecteinascidin 743 does not predict gender-dependent toxicity in humans

Clinical Cancer Research

Volumn 8, Issue 9, 2002, Pages 2952-2962

  Reid, Joel M ^a   Kuffel, Mary J ^a   Ruben, Stacie L ^a   Morales, Jose J ^b   Rinehart, Kenneth L ^b   Squillace, David P ^a   Ames, Matthew M ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 METHYLCHOLANTHRENE; CYTOCHROME P450 2A; CYTOCHROME P450 2A2; CYTOCHROME P450 2C; CYTOCHROME P450 2E; CYTOCHROME P450 3A; CYTOCHROME P450 3A2; CYTOCHROME P450 INHIBITOR; CYTOCHROME P450 ISOENZYME; DEXAMETHASONE; NSC 648766; PHENOBARBITAL; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; TRABECTEDIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILIARY EXCRETION; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG HALF LIFE; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LIVER METABOLISM; LIVER TOXICITY; MALE; MASS SPECTROMETRY; NONHUMAN; PREDICTION; PRIORITY JOURNAL; RAT; SEX DIFFERENCE; XENOGRAFT;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; BILE; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DIOXOLES; DNA, COMPLEMENTARY; ENZYME INHIBITORS; FEMALE; HALF-LIFE; HUMANS; IMMUNE SERA; ISOQUINOLINES; MALE; MARINE TOXINS; MICROSOMES, LIVER; MOLECULAR STRUCTURE; NADP; OXIDOREDUCTASES, N-DEMETHYLATING; PROTEIN ISOFORMS; RATS; RATS, INBRED F344; RECOMBINANT FUSION PROTEINS; SEX CHARACTERISTICS; STEROID HYDROXYLASES; SUBSTRATE SPECIFICITY; TETRAHYDROISOQUINOLINES; UROCHORDATA;

EID: 0036715309     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Antitumor tetrahydroisoquinoline alkaloids from the colonial ascidian Ecteinascidia turbinata
2. Ecteinascidins 729, 743, 745, 759A. 759B, and 770: Potent antitumor agents from the Caribbean tunicate Ecteinascidia turbinata
3. DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata
4. Mechanism for the catalytic activation of ecteinascidin 743 and its subsequent alkylation of guanine N2
5. Preclinical pharmacology of ecteinascidin 729, a marine natural product with potent antitumor activity
6. Toxicity of ecteinascidin 729 (NSC-638718) in CD2F1 mice and beagle dogs
7. Ecteinascidin-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts
8. Ecteinascidin 743 induces protein-linked DNA breaks in human colon carcinoma HCT116 cells and is cytotoxic independently of topoisomerase I expression
9. Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair
10. Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743
11. Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDRI activation
12. Ecteinascidin-743: A marine-derived compound in advanced, pretreated sarcoma patients-preliminary evidence of activity
13. Phase I pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors
14. Phase I pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies
15. Preclinical toxicology studies of Ecteinascidin 743
16. Toxicity of ecteinascidin 743 in female Fischer-344 rats administered i. V. in a multiple-dose regimen
17. Sex-dependent metabolism of xenobiotics
18. Gender effects in pharmacokinetics and pharmacodynamics
19. Metabolism of Taxol by human hepatic microsomes and liver slices: Participation of cytochrome P450 3A4 and an unknown P450 enzyme
20. Enzyme-structure relationships in the endoplasmic reticulum of rat liver
21. Cleavage of structural proteins during the assembly of the head of bacteriophage T4
22. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedures and some applications
23. Microtubule modulation of biliary excretion of endogenous and exogenous hepatic lysosomal constituents
24. Analysis of ecteinascidin 743, a new potent marine-derived anticancer drug, in human plasma by high-performance liquid chromatography in combination with solid-phase extraction
25. Bioanalytical method validation - A revisit with a decade of progress
26. Cytochromes P450 in rats: Structures, functions, properties and relevant human forms
27. The biosynthesis of tuberin from tyrosine and glycine: Observations on the stereochemistry associated with the conversion of glycine through methylenetetrahydrofolate into methenyltetrahydrofolate
28. Action de l'acide paranitroperbenzoique sur le tetrafluoroborate de N-methyl-3, 4-dihydroisoquinolinium. Formation d'un sel d'oxaziridinium
29. Regulation of two members of the steroid-inducible cytochrome P450 subfamily (3A) in rats
30. Expression and inducibility of cytochrome P450 3A9 (CYP3A9) and other members of the CYP3A subfamily in rat liver
31. P450 in the rat and man: Methods of investigation, substrate specificities and relevance to cancer
32. cDNA cloning and characterization of a novel member of steroid-induced cytochrome P450 3A in rats
33. Isolation and characterization of a new rat P450 (CYP3A18) cDNA encoding P4506β-2 catalyzing testosterone 6β- and 16α-hydroxylations
34. Induction of the male-specific cytochrome P450 3A2 in female rats by phenytoin
35. cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome P450
36. Identification and functional characterization of eight CYP3A4 protein variants
37. The human cytochrome P450 3A locus. Gene evolution by capture of downstream exons
38. Genomic organization of the human CYP3A locus: Identification of a new, inducible CYP3A gene
39. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression
40. CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: Evidence for an allelic variant with altered catalytic activity
41. Selective expression of cytochrome P450 CYP3A mRNAs in embryonic and adult human liver
42. The erythromycin breath test as a predictor of cyclosporine blood levels
43. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians
44. Interindividual differences in hepatic expression of CYP3A4: Relationship to genetic polymorphism in the 5′-upstream regulatory region
45. Cytochrome P4503A (CYP3A) metabolism: Prediction of in vivo activity in humans
46. Heterogeneity of CYP3A isoforms metabolizing erythroycin and cortisol
47. Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450, studies in rats and patients
48. P450 3A activity and cyclosporine dosing in kidney and heart transplant recipients
49. Contribution of human CYP3A subfamily members to the 6-hydroxylation of chlorzoxazone
50. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: Effect of ketoconazole
51. Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A
52. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism
53. Gene conversion and differential regulation in the rat P-450 IIA gene subfamily. Purification, catalytic activity, cDNA and deduced amino acid sequence, and regulation of an adult male-specific hepatic testosterone 15 α-hydroxylase
54. Search for metabolites of ecteinascidin 743, a novel, marine-derived, anti-cancer agent, in man
55. A Phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies